Supplementary Table 3– Servant dataset				
Characteristic		N=343 (%) (except when data missing)		
Age	≤40	78 (23%)		
	>40	265 (77%)		
Tumor Stage	T1	216 (63%)		
	T2-3	125 (37%)		
Nodal Status	Negative	215 (64%)		
	Positive	128 (36%)		
Recurrence Status	Local recurrence	119 (35%)		
	No local recurrence	224 (65%)		
Surgical Margin	Negative	318 (94%)		
	Positive	22 (6%)		
Boost RT (≥66 Gy)	Yes	247 (73%)		
	No	97 (27%)		
Adjuvant CT/HT	No	201 (59%)		
	Yes	141 (41%)		
Adjuvant CT	No	209 (61%)		
	Yes	133 (39%)		
Adjuvant HT	No	311 (91%)		
	Yes	31 (9%)		
Grade	I/II	202 (60%)		
	III	137 (40%)		
Mitotic Index	MI 1	174 (53%)		
	MI 2	59 (18%)		
	MI 3	96 (29%)		
LVI	Absent	254 (96%)		
	Present	11 (4%)		
p53 Mutation	Absent	73 (75%)		

	Present	35 (19%)	
ER	Positive	267 (78%)	
	Negative	76 (22%)	
PR	Positive	204 (59%)	
	Negative	139 (41%)	
HER2/neu	Positive	52 (15%)	
	Negative	291 (85%)	
TNBC	Yes	64 (19%)	
	No	279 (81%)	

Supplementary Table– Clinical characteristics of the tumors in the Servant dataset. This study from a French (57%) and Dutch (43%) cohort of patients which had clinical follow-up data that allowed for the analysis of the effect of AR expression level on local recurrence. Abbreviations: RT, radiation therapy, CT, chemotherapy; HT, hormone therapy; LR, local recurrence; LVI, lobular vascular in situ; MI, mitotic index; TNBC, triple-negative breast cancer.

Characteristic		N=295 (%) (except when data missing)
Age	<40	63 (21%)
	40-49	183 (62%)
	≥ 50	49 (17%)
Tumor Stage	T1	155 (53%)
	T2-3	140 (47%)
Nodal Status	0 nodes	151 (51%)
	1-3 nodes	106 (36%)
	≥4 nodes	38 (13%)
Recurrence Status	No local recurrence	268 (91%)
	Local recurrence	27 (9%)
Adjuvant CT	No	185 (63%)
v	Yes	110 (37%)

Adjuvant HT	No Yes	255 (96%) 40 (14%)
Grade	I/II III	176 (60%) 119 (40%)
LVI	Absent Present	185 (63%) 110 (37%)
ER	Positive Negative	226 (77%) 69 (23%)

Supplementary Table– Clinical characteristics of the tumors in the van de Vijver dataset. This study from a Dutch cohort of patients which had clinical follow-up data that allowed for the analysis of the effect of AR expression on local recurrence. Abbreviations: CT, chemotherapy; HT, hormone therapy; LR, local recurrence; LVI, lymphovascular invasion.